Head of Precision Medicine for Merck & Co., Inc. US Oncology
Dennis Flannelly is an innovative and results-oriented business leader with experiences in early and late-stage product development, core in-line pharmaceutical product tactical execution, and managing medium to large-scale diagnostics businesses.
More About Dennis
Prior to rejoining Merck, known as MSD outside of the United States and Canada, Flannelly was Vice President & General Manager of the Immunodiagnostics Business at PerkinElmer Inc. While in this role, he led the largest acquisition in PerkinElmer history of Euroimmun. Dennis also served on the Supervisory Board of Euroimmun with PerkinElmer CEO.
Prior to leading the Immunodiagnostics business at PerkinElmer, Dennis served as Vice President of the Maternal-Fetal Health business. In his role, he led the business unit and was responsible for the strategic planning efforts, execution planning, and identification of new growth opportunities. While in the role, Flannelly led the acquisition and integration of Vanadis Diagnostics, an early stage non-invasive prenatal diagnostic test. It launched into the market in late 2018.
Prior to joining PerkinElmer, he worked at Thermo Fisher Scientific as Global Director Clinical Marketing, where he led all clinical marketing efforts for the ImmunoDiagnostics Business. Previously he served as Head of US Marketing, where he was responsible for marketing strategy and execution for the allergy and immunology diagnostic franchises. He also played a key role in the integration of Phadia into Thermo Fisher Scientific. Before entering diagnostics, Dennis worked for Merck & Co. Inc., gaining experiences in sales, early/late-stage product development, and core in-line product marketing for mid-range and blockbuster products in neurology, arthritis & analgesia, respiratory and cardiovascular disease product lines.
Flannelly holds a Bachelor of Science in marketing from Villanova University and a Master of Business Administration from Saint Joseph’s University.